Results 1 to 10 of about 29,799 (243)

A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra‐Long‐Acting β2‐Agonists Used for Asthma and COPD [PDF]

Pharmacology Research & Perspectives
β‐agonists have been used in asthma for 120 years. There are two recent changes: ultra‐long‐acting agonists for COPD and new asthma guidelines recommending formoterol/ICS inhalers phasing out short‐acting salbutamol inhalers. Few studies directly compare
Richard G. W. Proudman, Jillian G. Baker
doaj   +3 more sources

Long-acting β2-adrenergic receptor agonist in pediatric asthma

Allergology International, 2004
Long-acting β2-adrenergic receptor agonists (LABA), a class of agents for the long-term management of childhood bronchial asthma, are recommended for use in combination with steroid inhalation for the treatment of the morning dip in severe childhood ...
Shigemi Yoshihara, Yumi Yamada, Toshio Abe, Osamu Arisaka   +3 more
doaj   +2 more sources

β2-Adrenergic receptor (β2-AR) agonist formoterol suppresses differentiation of L6 myogenic cells by blocking PI3K–AKT pathway

Animal Cells and Systems, 2019
β2-Adrenergic receptor (β2-AR) is implicated in muscle metabolic activities such as glycogen metabolism, glucose uptake, lipolysis and muscle growth. However, the functional role of β2-AR in the differentiation of skeletal muscle is largely unknown. Here,
So-Hyeon Kim, Sun-Ju Yi, Hyerim Lee, Ji-Hyun Kim, Myung-ju Oh, Eun-Ju Song, Kyunghwan Kim, Byung H. Jhun   +7 more
doaj   +2 more sources

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease [PDF]

BMC Pulmonary Medicine, 2021
Background In chronic obstructive pulmonary disease (COPD) patients, combination treatment with long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA) increases forced expiratory volume in one second and reduces symptoms compared to ...
Masato Muraki, Yuki Kunita, Ken Shirahase, Ryo Yamazaki, Soichiro Hanada, Hirochiyo Sawaguchi, Yuji Tohda   +6 more
doaj   +2 more sources

Effect of long-acting β2-agonist and corticosteroid combination treatment on parotid glands of rats (histological and immunohistochemical study) [PDF]

BMC Oral Health
Background Bronchial asthma is a common chronic condition frequently managed with corticosteroids, β2 receptor agonists, or their combination. While these therapies effectively control respiratory symptoms, emerging evidence suggests they may adversely ...
Lobna Mohamed Nabil, Dalia Riad
doaj   +2 more sources

Long-acting β2 agonist (LABA) with a long-acting muscarinic receptor antagonist (LAMA) promotes human airway smooth muscle (HASM) relaxation and circumvents β2 adrenergic receptor tachyphylaxis [PDF]

Respiratory Research
To fill the gap in the knowledge between clinical studies and pre-clinical mechanistic studies using combined LABA/LAMA therapy, we hypothesized that the combination is more effective in attenuating excitation-contraction (E-C) coupling compared to ...
Joseph Jude, Nikhil Karmacharya, Rinzhin T. Sherpa, Thomas G. O’Riordan, Cynthia J. Koziol-White, Reynold A. Jr. Panettieri   +5 more
doaj   +2 more sources

Long-acting β2-agonists increase fluticasone propionate-induced mitogen-activated protein kinase phosphatase 1 (MKP-1) in airway smooth muscle cells. [PDF]

PLoS ONE, 2013
Mitogen-activated protein kinase phosphatase 1 (MKP-1) represses MAPK-driven signalling and plays an important anti-inflammatory role in asthma and airway remodelling. Although MKP-1 is corticosteroid-responsive and increased by cAMP-mediated signalling,
Melanie Manetsch, Md Mostafizur Rahman, Brijeshkumar S Patel, Emma E Ramsay, Nowshin N Rumzhum, Hatem Alkhouri, Qi Ge, Alaina J Ammit   +7 more
doaj   +1 more source

Long-Acting β2 Adrenergic Receptor Agonist Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesion by Regulating Keratinocyte Proliferation and Apoptosis

Frontiers in Pharmacology, 2022
Psoriasis is a chronic inflammatory disease that affects approximately 1%–5% of the population worldwide. Considering frequent relapse, adverse drug reactions, and large costs of treatment, it is urgent to identify new medications for psoriasis ...
Rui Xu, Rui Xu, Shi Feng, Shi Feng, Zhou Ao, Zhou Ao, Yingxiang Chen, Yingxiang Chen, Congping Su, Congping Su, Xiuling Feng, Qin Fu, Qin Fu, Xiaoyan Yang, Xiaoyan Yang   +14 more
doaj   +1 more source

Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators

Respiratory Medicine Case Reports, 2019
Immune checkpoint inhibitors (ICIs) have been used to treat lung cancer. Several types of ICI-related interstitial lung diseases have been reported, including organizing pneumonia, non-specific interstitial pneumonia, and diffuse alveolar damage. However,
Takafumi Yamaya, Hwang Moon Hee, Takayuki Aoyagi, Tatsuya Ogimoto, Naoki Yamada, Ryoichi Ishikawa, Erika Nakai, Kenta Nishi, Chie Yoshimura, Yasuo Nishizaka   +9 more
doaj   +1 more source

Transdermal Tulobuterol Patch, a Long-Acting β2-Agonist

Allergology International, 2012
Tulobuterol patch (Hokunalin™ Tape), which contains a β2-adrenergic agonist, is the first bronchodilator to be available as a transdermal patch. This drug delivery system ensures that the time at which the peak drug concentration in the blood is reached ...
Gen Tamura, Masakazu Ichinose, Yoshinosuke Fukuchi, Terumasa Miyamoto   +3 more
doaj   +1 more source